These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14709715)

  • 1. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999.
    Smith DK; Gardner LI; Phelps R; Hamburger ME; Carpenter C; Klein RS; Rompalo A; Schuman P; Holmberg SD;
    J Urban Health; 2003 Dec; 80(4):676-88. PubMed ID: 14709715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use.
    Kapadia F; Cook JA; Cohen MH; Sohler N; Kovacs A; Greenblatt RM; Choudhary I; Vlahov D
    Addiction; 2005 Jul; 100(7):990-1002. PubMed ID: 15955015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.
    Yang CH; Huang YF; Hsiao CF; Yeh YL; Liou HR; Hung CC; Yang SY
    HIV Med; 2008 Aug; 9(7):535-43. PubMed ID: 18554309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
    Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
    J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.
    Croxford S; Kitching A; Desai S; Kall M; Edelstein M; Skingsley A; Burns F; Copas A; Brown AE; Sullivan AK; Delpech V
    Lancet Public Health; 2017 Jan; 2(1):e35-e46. PubMed ID: 29249478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013.
    Johnson NB; Hayes LD; Brown K; Hoo EC; Ethier KA;
    MMWR Suppl; 2014 Oct; 63(4):3-27. PubMed ID: 25356673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.
    Brady MT; Oleske JM; Williams PL; Elgie C; Mofenson LM; Dankner WM; Van Dyke RB;
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):86-94. PubMed ID: 20035164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.
    Sackoff JE; Hanna DB; Pfeiffer MR; Torian LV
    Ann Intern Med; 2006 Sep; 145(6):397-406. PubMed ID: 16983127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users.
    van Haastrecht HJ; van Ameijden EJ; van den Hoek JA; Mientjes GH; Bax JS; Coutinho RA
    Am J Epidemiol; 1996 Feb; 143(4):380-91. PubMed ID: 8633622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment.
    Palella FJ; Baker RK; Buchacz K; Chmiel JS; Tedaldi EM; Novak RM; Durham MD; Brooks JT;
    AIDS; 2011 Sep; 25(15):1865-76. PubMed ID: 21811144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killer.
    Simmons RD; Ciancio BC; Kall MM; Rice BD; Delpech VC
    HIV Med; 2013 Nov; 14(10):596-604. PubMed ID: 23672663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study.
    Hessol NA; Kalinowski A; Benning L; Mullen J; Young M; Palella F; Anastos K; Detels R; Cohen MH
    Clin Infect Dis; 2007 Jan; 44(2):287-94. PubMed ID: 17173233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes of death and factors associated with early death among human immunodeficiency virus (HIV)-infected persons in Singapore: pre-highly active antiretroviral therapy (HAART) and Peri-HAART.
    Chow A; Tey J; Win MK; Leo YS
    Ann Acad Med Singap; 2012 Dec; 41(12):563-70. PubMed ID: 23303113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.
    Crum NF; Riffenburgh RH; Wegner S; Agan BK; Tasker SA; Spooner KM; Armstrong AW; Fraser S; Wallace MR;
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):194-200. PubMed ID: 16394852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers.
    Sabin CA; Smith CJ; Youle M; Lampe FC; Bell DR; Puradiredja D; Lipman MC; Bhagani S; Phillips AN; Johnson MA
    AIDS; 2006 Jan; 20(1):67-71. PubMed ID: 16327321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.
    Antiretroviral Therapy Cohort Collaboration (ART-CC)
    Antivir Ther; 2015; 20(1):21-8. PubMed ID: 24675571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.